Spontaneous coronary artery dissection associated with pregnancy appears more clinically severe and potentially less likely to result in a favorable recovery. Karol E. Watson, MD, PhD, FACC (@kewatson), summarizes a recent study: https://t.co/FudA8QsQnn
#FlashbackFriday to our fellows covering our @UCLA IM residents on CCU, so they could enjoy their retreat!
#Bruinhearts always showing up for each other and our house staff 💙💛💙
And many thanks to those similarly covering Memorial Day weekend 🫡🫀
@NEJMClinician@kewatson@djc795 And Karol’s commentary on CHAMPION-AF is spot on, blunt but incisive!
It is hard to see how anyone can look at the results and declare it is a win for Watchman FLX.
@NEJMClinician@djc795@kewatson Excellent discussion!
Not sure if the distinction between DM with atherosclerosis and without atherosclerosis subset in VESALIUS-CV is as sharp as the investigators’ claims. Baseline CV or all-cause deaths and treatment benefit is indistinguishable among the 2 groups.
Our very own @kewatson co-authored @CircAHA editorial calling 2026 dyslipidemia guidelines "a more precise individualized & equitable" framework for ASCVD prevention. ABC members co-wrote the guidelines. Now they're leading the conversation. https://t.co/Q016pacrcZ
#ACC26 finishes & as always proud of our @UCLAHealth presence, led by our housestaff & alumni!
🔥work with 25+ abstracts/talks/more �� to the mentors who inspire them
And congrats to @ACCinTouch 🌟#KatieBerlacher whose MedEd impact reaches farther than u will ever know ❤️
It’s a #MATCH 💙🎊💛!
Welcome to the newest members of our #Bruinhearts Family!
We are so thrilled to have you all join us, and congratulations on your incredible achievements! The future of cardiology is bright and forever beats blue and gold ⭐️💫.
CORE TIMi 72a/b presented as #LBCT#AHA25 studying olezarsen in severe hypertriglyceridemia with primary endpoint percent change in TG
♥️ Global study 1063 patients
♥️placebo compared with two doses
♥️1/4 female 👎🏽
🎯62% placebo control ⤵️ in TG
🎯 significant ⤵️ in non HDL: many achieved TG <150 & 85% <500! 👏🏽
🎯⤵️ in pancreatitis with tx NNT=4
🎯 safe esp at 50 mg dose
📎 https://t.co/W0oXXAnWeM
@ionispharma@NEJM
Remarkable contributions to the field expanding a life saving therapy-great to see the two legends on the stage for 20th Annual VT Symposium- Mark Josephson Memorial Lecture. Our beloved Mark would indeed be smiling! @DrRoderickTung@VTSymposium
So lovely to spend time with some of our favorite people! Lovely to be able to have a hike & breakfast with @rblument1 & @WendyPost9 today before their wedding they are attending tonight & before @SmidtHeart GR on Tuesday! We loved being able to see you both! #CVPrev & #friendship are some of the best things in life!
Amgen announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that evolocumab significantly reduced the risk of MACE in individuals without a prior history of heart attack or stroke
12,000 high-risk patients, median of 4.5 years
@kewatson
Data from the COMBINE-AF substudy suggest it may be safe and beneficial to switch frail older patients with atrial fibrillation from warfarin to a direct-acting oral anticoagulant. https://t.co/5zkcv5gIda
#CardioTwitter@kewatson